Historical Valuation
AN2 Therapeutics Inc (ANTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.06. The fair price of AN2 Therapeutics Inc (ANTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.30
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
AN2 Therapeutics Inc (ANTX) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 1.59 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 1.72, the current P/B ratio is about -100.00% higher. AN2 Therapeutics Inc (ANTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -75.82%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -60.05% , the current FCF yield is about -100.00% lower.
P/B
Median3y
1.59
Median5y
1.72
FCF Yield
Median3y
-75.82
Median5y
-60.05
Competitors Valuation Multiple
AI Analysis for ANTX
The average P/S ratio for ANTX competitors is 2.82, providing a benchmark for relative valuation. AN2 Therapeutics Inc Corp (ANTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ANTX
1Y
3Y
5Y
Market capitalization of ANTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ANTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ANTX currently overvalued or undervalued?
AN2 Therapeutics Inc (ANTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.06. The fair price of AN2 Therapeutics Inc (ANTX) is between to according to relative valuation methord.
What is AN2 Therapeutics Inc (ANTX) fair value?
ANTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AN2 Therapeutics Inc (ANTX) is between to according to relative valuation methord.
How does ANTX's valuation metrics compare to the industry average?
The average P/S ratio for ANTX's competitors is 2.82, providing a benchmark for relative valuation. AN2 Therapeutics Inc Corp (ANTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for AN2 Therapeutics Inc (ANTX) as of Jan 10 2026?
As of Jan 10 2026, AN2 Therapeutics Inc (ANTX) has a P/B ratio of 0.00. This indicates that the market values ANTX at 0.00 times its book value.
What is the current FCF Yield for AN2 Therapeutics Inc (ANTX) as of Jan 10 2026?
As of Jan 10 2026, AN2 Therapeutics Inc (ANTX) has a FCF Yield of 0.00%. This means that for every dollar of AN2 Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for AN2 Therapeutics Inc (ANTX) as of Jan 10 2026?
As of Jan 10 2026, AN2 Therapeutics Inc (ANTX) has a Forward P/E ratio of -1.41. This means the market is willing to pay $-1.41 for every dollar of AN2 Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for AN2 Therapeutics Inc (ANTX) as of Jan 10 2026?
As of Jan 10 2026, AN2 Therapeutics Inc (ANTX) has a Forward P/S ratio of 0.00. This means the market is valuing ANTX at $0.00 for every dollar of expected revenue over the next 12 months.